The level of adiponectin differs in patients with HBV compared with non-HBV/NAFLD patients where, for example, the level of adiponectin decreases with the development of MetS and NASH yet may increase in patients with cirrhosis regardless of metabolic factors (133, 252, 313). This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.